Work

Abstract 685: PARP inhibitor MK-4827 is synthetic lethal for tumors with homologous recombination defects associated with ATM-deficiency, PTEN-deletion and microsatellite instability (MSI)

Year: 2010

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am10-685

Authors: Giuseppe Roscilli, Gerald Gavory, Stefania Lamartina, Emanuele Marra, Brian Dolinski, Sybil Williams, Cem Elbi, Philip Jones, Christopher L. Carpenter, Carlo Toniatti

Institutions: Merck Serono S.p.A. (Italy), Cancer Research Wales

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2033108966

Cites:

Cited by: 3

Related to: 10